From Cydy website presentation. mTNBC • Phase
Post# of 148165
mTNBC
• Phase 1b/2 initiated – unmet medical need
• Granted Fast-Track designation by FDA based on a greater than 98%
reduction of metastatic tumor volume in a murine xenograft model
• Sept 2019 – Four patients injected
• Based on current results, we will file Breakthrough Therapy Designation in
January 2020